Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Post by everswannon Jan 31, 2008 9:45am

112 Views

Post# 14295488

I honestly wonder what Christine is thinking

I cannot "believe" that this is a "dumb" move. This management team has done awesome moves in the last 2 years. BMO is acting as adviser, arguably the best one in Town. Internal reason are not provided. Certainly next conference call, I'll be asking why. My rationale is that there is more than meet the eyes. Anyhow, the bleeding stops here.

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario